Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

TMPRSS2-ERG fusion transcripts in matched urine and needle rinse material after biopsy for the detection of prostate cancer: really a step forward?

Stephan C, Jung K.

Clin Chem. 2013 Jan;59(1):9-10. doi: 10.1373/clinchem.2012.196360. Epub 2012 Nov 7. No abstract available.

2.

TMPRSS2-ERG fusion transcripts in matched urine and needle rinse material after biopsy for the detection of prostate cancer.

Bories PN, Younes P, Zerbib M, Denjean L, Popovici T, Cynober L, Delongchamps NB.

Clin Chem. 2013 Jan;59(1):245-51. doi: 10.1373/clinchem.2012.192260. Epub 2012 Oct 8.

3.

TMPRSS2-ERG fusion transcripts expression in patients referred for prostate biopsy: combining detection in urine and needle rinse material.

Delongchamps NB, Younes P, Denjean L, Zerbib M, Bories PN.

World J Urol. 2015 Jun;33(6):807-11. doi: 10.1007/s00345-014-1359-5. Epub 2014 Jul 5.

PMID:
24997128
4.

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.

Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA.

Clin Cancer Res. 2007 Sep 1;13(17):5103-8.

5.

TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.

Rostad K, Hellwinkel OJ, Haukaas SA, Halvorsen OJ, Øyan AM, Haese A, Budäus L, Albrecht H, Akslen LA, Schlomm T, Kalland KH.

APMIS. 2009 Aug;117(8):575-82. doi: 10.1111/j.1600-0463.2009.02517.x.

PMID:
19664128
6.

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.

Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.

Mod Pathol. 2008 Feb;21(2):67-75. Epub 2007 Dec 7.

7.

Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.

Salagierski M, Schalken JA.

J Urol. 2012 Mar;187(3):795-801. doi: 10.1016/j.juro.2011.10.133. Epub 2012 Jan 15. Review.

PMID:
22245323
8.

Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.

Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, Venkateswaran V, Narod SA, Seth A.

Cancer Biol Ther. 2007 Jan;6(1):40-5.

PMID:
17172822
9.

Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.

Robert G, Jannink S, Smit F, Aalders T, Hessels D, Cremers R, Mulders PF, Schalken JA.

Prostate. 2013 Jan;73(2):113-20. doi: 10.1002/pros.22546. Epub 2012 Jun 5.

PMID:
22674214
10.

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.

Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, Trapman J.

Clin Cancer Res. 2009 Oct 15;15(20):6398-403. doi: 10.1158/1078-0432.CCR-09-1176. Epub 2009 Oct 13.

11.

Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer HA, Bögemann M, Miller K, Friedersdorff F.

Clin Chem. 2013 Jan;59(1):280-8. doi: 10.1373/clinchem.2012.195560. Epub 2012 Dec 4.

12.

Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.

Winnes M, Lissbrant E, Damber JE, Stenman G.

Oncol Rep. 2007 May;17(5):1033-6.

PMID:
17390040
13.

Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.

Rubio-Briones J, Fernández-Serra A, Calatrava A, García-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, López-Guerrero JA.

J Urol. 2010 May;183(5):2054-61. doi: 10.1016/j.juro.2009.12.096. Epub 2010 Mar 19.

PMID:
20303538
14.

Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer.

Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A.

Br J Cancer. 2009 May 19;100(10):1603-7. doi: 10.1038/sj.bjc.6605058. Epub 2009 Apr 28.

15.

TMPRSS2:ERG gene fusion a new genetic marker for prostate cancer progression.

Macaluso M, Giordano A.

Cancer Biol Ther. 2007 Jan;6(1):46-7. No abstract available.

PMID:
17224639
16.

Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.

Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J.

Cancer Res. 2009 Jan 15;69(2):640-6. doi: 10.1158/0008-5472.CAN-08-2008.

17.

Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.

Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramäki OR, Visakorpi T.

Clin Cancer Res. 2010 May 15;16(10):2845-51. doi: 10.1158/1078-0432.CCR-09-2505. Epub 2010 May 4.

18.

[Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].

Dai MJ, Chen LL, Zheng YB, Chen W, Tao ZH, Weng ZL, Wu XL, Li CD, Chen ZG, Chen XD, Shi SB.

Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):669-73. Chinese.

PMID:
18642766
19.

Androgen regulation of ETS gene fusion transcripts in prostate cancer.

Gasi D, Trapman J.

Methods Mol Biol. 2011;776:335-48. doi: 10.1007/978-1-61779-243-4_19.

PMID:
21796535
20.

A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants.

Lu Q, Nunez E, Lin C, Christensen K, Downs T, Carson DA, Wang-Rodriguez J, Liu YT.

Nucleic Acids Res. 2008 Nov;36(20):e130. doi: 10.1093/nar/gkn585. Epub 2008 Sep 15.

Supplemental Content

Support Center